[2] The Government Pension Fund of Norway has excluded the company from investments since 21 December 2021, since the company "uses and sells body parts from pangolins which is a globally endangered species".

[4] As of December 31, 2007, the company had 12 subsidiaries, engaged in the pharmaceutical industry, and four major associates, involved in securities, investment and biotechnological research.

For the fiscal year of 2007, YBG obtained approximately 99% of its total revenue from the sale of pharmaceutical products.

On 25 July 2022, Yunnan Baiyao Group signed a cooperation agreement with Huawei for research and development of artificial intelligence drugs.

[6] More specifically, the company "uses and sells body parts from pangolins which is a globally endangered species".